ACCELEREATED HYPERFRACTIONATED WITH UNEVEN CRUSHING DAILY DOSE WITH CHEMORADIATION TREATMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER.
Abstract
This study presents the results of chemoradiation treatment with accelerated hyperfractionated regime with uneven crushing daily dose in patients with unresectable non-small cell lung cancer. The study included 187 patients with confirmed diagnosis of non-small cell lung cancer. Patients were divided into three groups: the first (control) group included 75 patients who underwent radiotherapy in conventional fractionation regimen (60–66 Gy in 30–33 daily fractions) with sequential 2–4 cycles of chemotherapy of cisplatin + etoposide. In the second (intermediate group) included 66 patients who underwent radiation therapy to hyperfractionated accelerated regimen (1 Gy and 1.5 Gy b.i.d. in 48–56 fractions) with sequential 2–4 cycles of chemotherapy of cisplatin + etoposide. In the third (main) group consisted of 46 patients who underwent radiation therapy to hyperfractionated accelerated regimen (1 Gy and 1.5 Gy b.i.d. in 48–56 fractions) with simultaneous 2 cycles of cisplatin + etoposide. Complete and partial response rate was 60.0 % in the control group, 89.4 % in the intermediate group and 76.0 % in the study group. Five-year overall and disease-free survival rates were in control, intermediate and main groups, 6.6 %, 10.5 %, 21.4 % and 2.5 %, 10.1 %, 16.4 %, respectively.
About the Authors
D. V. Gogolin
MRRC of the Russian Ministry of Health, Obninsk
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
I. A. Gulidov
MRRC of the Russian Ministry of Health, Obninsk
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Ju. S. Mardynskij
MRRC of the Russian Ministry of Health, Obninsk
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
I. N. Ivanova
MRRC of the Russian Ministry of Health, Obninsk
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Ju. A. Ragulin
MRRC of the Russian Ministry of Health, Obninsk
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
L. V. Kursova
MRRC of the Russian Ministry of Health, Obninsk
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
Russian Federation
4, Korolyeva Street, 249036-Obninsk, Kaluga region
References
1. Akimov A.A., Il’in A.V. Role of dose fractionation to increase the efficiency of radiation therapy // Voprosy onkologii. 2005. № 6. P. 647–655. [in Russian]
2. Akimov A.A., Il’in A.V. Aaccelerated hyper fractionation: radiobiological justification and clinical issues // Medicinskaja radiologija i radiacionnaja bezopasnost’. 2004. Vol. 49 (2). P. 40–50. [in Russian]
3. Bychkov M.B. Role of chemotherapy in treatment of non-small cell lung cancer // Materialy IV ezhegodnoj Rossijskoj onkologicheskoj konferencii. M., 2000. S 10–13. [in Russian]
4. Kaprin A.D., Starinskij V.V., Petrova G.V. Злокачественные новообразования в России в 2013 году (Заболеваемость и смертность). M., 2015. 250 p. [in Russian]
5. Mardynskij Ju.S., Gulidov I.A., Ivanova I.N., Kursova L.V., Zolotkov A.G., Kudrjavcev D.V., Ragulin Ju.A., Gogolin D.V. Results of continuous hyperfractionated radiotherapy in treatment of non-small cell lung cancer // Sibirskij onkologicheskij zhurnal. 2010. № 2. P. 11–14. [in Russian]
6. Belani C.P., Wang W., Johnson D., Wagner H., Schiller J., Veeder M., Mehta M. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer // J. Clinic. Oncol. 2005. Vol. 23 (16). P. 3760–2767.
7. Belderbos J., Uitterhoeve L., van Zandwijk N., Belderbos H., Rodrigus P., van de Vaart P., Price A., van Walree N., Legrand C., Dussenne S., Bartelink H., Giaccone G., Koning C. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable nonsmall cell lung cancer (EORTC 08972-22973) // Eur. J. Cancer. 2007. Vol. 43 (1). P. 114–121.
8. Curran W.J., Scott C., Langer R. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small-cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410 // Proc. Am. Soc. Clin. Oncol. 2000. Abstr. 1891.
9. D’Addario G., Felip E. ESMO Guidelines Working Group. Nonsmall-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up // Ann. Oncol. 2008. Vol. 19, Suppl. 2. ii. 39−40. doi: 10.1093/annonc/mdn081.
10. Jeremic B., Milicic B. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with earlystage nonsmall cell lung cancer // Cancer. 2008. Vol. 112 (4). P. 876–884. doi: 10.1002/cncr.23240.
11. Jeremic B., Milicic B., Milisavljevic S. Clinical prognostic factors in patients with locally advanced (stage III) non-small cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 patients // Cancer. 2011. Vol. 117 (13). P. 2995–3003. doi: 10.1002/cncr.25910.
12. Jeremic B., Milicic B., Milisavljevic S. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients // Int. J. Radiat. Oncol. Biol. Phys. 2012. Vol. 82 (3). P. 1157–1163. doi: 10.1016/j.ijrobp.2011.04.016.
13. Kim M.K., Kim S.W., Choi E.K., Sohn H.J., Lee D.H., Suh Cheolwon, Lee J.S., Yang H.J., Hong J.S., Kim W.S. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial // J. Clin. Oncol. 2007. Vol. 2. Issue 8. p. S308. doi: 10.1097/01.JTO.0000283090.56099.
Review
For citations:
Gogolin D.V., Gulidov I.A., Mardynskij J.S., Ivanova I.N., Ragulin J.A., Kursova L.V. ACCELEREATED HYPERFRACTIONATED WITH UNEVEN CRUSHING DAILY DOSE WITH CHEMORADIATION TREATMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER. Siberian journal of oncology. 2014;(6):5-9. (In Russ.)
Views:
562
Email this article 
